Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Hereditary Cancer Group, |
RCV001779205 | SCV001623540 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 3 | 2021-05-03 | criteria provided, single submitter | curation | |
Labcorp Genetics |
RCV001882538 | SCV002177143 | pathogenic | Fanconi anemia complementation group O | 2021-11-02 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This premature translational stop signal has been observed in individual(s) with ovarian cancer (PMID: 22538716). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Val236Glyfs*16) in the RAD51C gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in RAD51C are known to be pathogenic (PMID: 20400964, 21990120, 24800917). |